Immune Thrombocytopenia Therapeutics
1. Doptelet patent expiration
Treatment: Treatment of thrombocytopenia in an adult patient with chronic liver disease who is scheduled to undergo a procedure; Treatment of thrombocytopenia in an adult patient with chronic
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7638536 | AKARX INC | 2-Acylaminothiazole derivative or salt thereof |
Jul, 2027
(1 year, 6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8765764 | AKARX INC | 2-acylaminothiazole derivative or salt thereof |
Jan, 2023
(2 years ago) | |
| US8338429 | AKARX INC | 2-acylaminothiazole derivative or salt thereof |
Jun, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-802) | Jun 26, 2022 |
| New Chemical Entity Exclusivity(NCE) | May 21, 2023 |
| Orphan Drug Exclusivity(ODE-246) | Jun 26, 2026 |
| New Indication(I-974) | Jul 24, 2028 |
Drugs and Companies using AVATROMBOPAG MALEATE ingredient
NCE-1 date: 21 May, 2022
Market Authorisation Date: 21 May, 2018
Dosage: TABLET
More Information on Dosage
DOPTELET family patents
2. Promacta patent expiration
Treatment: Treatment of idiopathic thrombocytopenic purpura (itp); Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; Treatmen...
PROMACTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7547719 | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jul, 2025
(5 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7160870 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
May, 2023
(2 years ago) | |
| US7160870 | NOVARTIS | Thrombopoietin mimetics |
Nov, 2022
(3 years ago) | |
| US8052995 | NOVARTIS | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(1 year, 6 months from now) | |
| US7332481 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(4 years ago) | |
| US6280959 | NOVARTIS | Metal complexes |
Oct, 2018
(7 years ago) | |
|
US6280959 (Pediatric) | NOVARTIS | Metal complexes |
Apr, 2019
(6 years ago) | |
| US7452874 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(4 years ago) | |
| US7795293 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
May, 2023
(2 years ago) | |
|
US7473686 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(4 years ago) | |
|
US7790704 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(4 years ago) | |
| US7790704 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(4 years ago) | |
|
US7332481 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(4 years ago) | |
|
US7452874 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(4 years ago) | |
| US7473686 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(4 years ago) | |
|
US8052995 (Pediatric) | NOVARTIS | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(2 years from now) | |
| US8071129 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(1 year, 6 months from now) | |
|
US7795293 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Nov, 2023
(2 years ago) | |
| US8052993 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(1 year, 6 months from now) | |
| US8828430 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(1 year, 6 months from now) | |
| US8052994 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(1 year, 6 months from now) | |
| US8062665 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(1 year, 6 months from now) | |
|
US8828430 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(2 years from now) | |
|
US7547719 (Pediatric) | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jan, 2026
(4 days from now) | |
|
US8052993 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(2 years from now) | |
|
US8052994 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(2 years from now) | |
|
US8062665 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(2 years from now) | |
|
US8071129 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
| New Indication(I-664) | Nov 16, 2015 |
| Orphan Drug Exclusivity(ODE) | Nov 20, 2015 |
| New Dosing Schedule(D-149) | Jun 11, 2018 |
| New Indication(I-711) | Jun 11, 2018 |
| Orphan Drug Exclusivity(ODE-75) | Aug 26, 2021 |
| Pediatric Exclusivity(PED) | Feb 26, 2022 |
| Orphan Drug Exclusivity(ODE-210) | Nov 16, 2025 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
NCE-1 date: 26 February, 2021
Market Authorisation Date: 20 October, 2011
Dosage: TABLET
How can I launch a generic of PROMACTA before it's drug patent expiration?
More Information on Dosage
PROMACTA family patents
3. Tavalisse patent
expiration
Treatment: Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (itp) who have had an insufficient response to a previo...
TAVALISSE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7538108 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Mar, 2026
(2 months from now) | |
| US7989448 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(5 months from now) | |
| US8163902 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(5 months from now) | |
| US8211889 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(10 days from now) | |
| US7449458 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Sep, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9737554 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(10 days from now) | |
| US8951504 | RIGEL PHARMS | (trimethoxyphenylamino) pyrimidinyl formulations |
Jul, 2032
(6 years from now) | |
| US8912170 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(5 months from now) | |
| US9283238 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(5 months from now) | |
| US9266912 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(10 days from now) | |
| US8445485 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(5 months from now) | |
| US8652492 | RIGEL PHARMS | Wet granulation using a water sequestering agent |
Nov, 2028
(2 years from now) | |
| US8263122 | RIGEL PHARMS | Wet granulation using a water sequestering agent |
Nov, 2030
(4 years from now) | |
| USRE48898 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(10 days from now) | |
| US8771648 | RIGEL PHARMS | (Trimethoxyphenylamino) pyrimidinyl formulations |
Jul, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2023 |
| Orphan Drug Exclusivity(ODE-174) | Apr 17, 2025 |
Drugs and Companies using FOSTAMATINIB DISODIUM ingredient
NCE-1 date: 17 April, 2022
Market Authorisation Date: 17 April, 2018
Dosage: TABLET
How can I launch a generic of TAVALISSE before it's drug patent expiration?
More Information on Dosage
TAVALISSE family patents